Effects of fluoroquinolones on the migration of human phagocytes through Chlamydia pneumoniae-infected and tumor necrosis factor alpha-stimulated endothelial cells.
Berger
Richard E
RE
D001372:Aza Compounds / Q000494:pharmacology; D002460:Cell Line; D002465:Cell Movement / Q000187:drug effects*; D018932:Chemokine CCL2 / Q000037:antagonists & inhibitors; D002690:Chlamydia Infections / Q000276:immunology*; D016993:Chlamydophila pneumoniae; D004730:Endothelium, Vascular / Q000276:immunology*; D024841:Fluoroquinolones / Q000494:pharmacology*; D000077734:Gatifloxacin; D006801:Humans; D016209:Interleukin-8 / Q000037:antagonists & inhibitors; D009000:Monocytes / Q000187:drug effects; D000077266:Moxifloxacin; D009504:Neutrophils / Q000187:drug effects; D015242:Ofloxacin / Q000494:pharmacology; D010587:Phagocytosis / Q000187:drug effects*; D011804:Quinolines / Q000494:pharmacology; D013268:Stimulation, Chemical; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology*
D001372:Aza Compounds; C111835:CCL2 protein, human; D018932:Chemokine CCL2; D024841:Fluoroquinolones; D016209:Interleukin-8; D011804:Quinolines; D014409:Tumor Necrosis Factor-alpha; D015242:Ofloxacin; D000077734:Gatifloxacin; D000077266:Moxifloxacin